After the 2012 Adcom meeting the FDA admitted they did not realize what a serious debilitating disease it is <sigh> - so the independent IOM and the NIH P2P reports helped them realize.
HEB has a big advantage - ampligen is the only drug to undergo pivotal phase II and phase III FDA trials. Not to mention 18+ years of cost recovery compassionate care treatment.
Market Data 
Markets 
AI
